Baird raised the firm’s price target on Haemonetics (HAE) to $99 from $87 and keeps an Outperform rating on the shares. The firm updated its model after its proprietary PDT Tracker showed continued strength in Rx’s which lends support for second half 2026 upside.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE: